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Synopsis    17 
Background: The better use of new and emerging data streams to understand the 18 
epidemiology of infectious disease and to inform and evaluate antimicrobial 19 
stewardship improvement programmes is paramount in the global fight against 20 
antimicrobial resistance.   21 
Objectives: To create a national informatics platform that synergises the wealth of 22 
disjointed, infection-related health data, building intelligence capability that allows 23 
rapid enquiry, generation of new knowledge and feedback to clinicians and policy 24 
makers.  25 
Methods:  A multi-stakeholder community, led by the Scottish Antimicrobial 26 
Prescribing Group, secured government funding to deliver a national program of 27 
work centred on three key aspects: technical platform development with record 28 
linkage capability across multiple datasets; a proportionate governance approach to 29 
enhance responsiveness; generation of new evidence to guide clinical practice. 30 
Results:  The National Health Service Scotland Infection Intelligence Platform (IIP) is 31 
now hosted within the national health data repository to assure resilience and 32 
sustainability.  New technical solutions include simplified “data views” of complex, 33 
linked datasets and embedded statistical programmes to enhance capability.  These 34 
developments have enabled responsiveness, flexibility and robustness in conducting 35 
population-based studies including a focus on intended and unintended effects of 36 
antimicrobial stewardship interventions and quantification of infection risk factors and 37 
clinical outcomes. 38 
Conclusion:  We have completed the build and test phase of IIP, overcoming the 39 
technical and governance challenges and produced new capability in infection 40 
informatics, generating new evidence for improved clinical practice. This provides a 41 
foundation for expansion and opportunity for global collaborations. 42 
 43 
 44 
Introduction  45 
Health systems are generating increasing volumes of routine clinical data as 46 
individuals interact with healthcare services. Strategies for surveillance of 47 
Antimicrobial resistance (AMR) and to address emergent problems, requires 48 
intelligent use of these new and emerging data streams to augment understanding of 49 
the epidemiology of infectious disease nationally, and contribute to the global public 50 
health effort against the threat of AMR.1-3    51 
In the UK, the AMR Strategy (2013-2018) defined as a key action, better access to 52 
and use of surveillance data, and recognised that current information on the impact 53 
of antimicrobial use on patient outcome and development of resistance was limited.4 54 
In response the Scottish Antimicrobial Management of Resistance Action Plan called 55 
for development of a National Health Service (NHS) Scotland Infection Intelligence 56 
Platform (IIP) recognising the importance of informatics to empower clinicians and 57 
healthcare systems to measure the intended and unintended consequences of 58 
interventions to prevent and treat infections.5 The IIP is an ambitious programme that 59 
aims to move to a position of enhanced connectivity of datasets to achieve a 60 
comprehensive, dynamic and responsive integrated informatics resource to support 61 
improvements in outcomes for patients with, or at risk of, infection.6  Underpinning 62 
this was our aim to create a more collegiate community of infection control and 63 
stewardship clinicians, supported by IIP, to deliver better informed clinical decisions, 64 
guide national policy and contribute to the global AMR effort.  In this paper we 65 
describe our early experiences and results in developing the IIP.  66 
Methods  67 
The AMR policy frameworks provided the stimulus and environment to build a broad 68 
coalition of clinicians and national stakeholders to co-create the vision for IIP – to 69 
improve patient outcomes and reduce harm from infection through innovative data 70 
integration to support clinicians within the NHS in Scotland. Led by the Scottish 71 
Antimicrobial Prescribing Group (SAPG) and supported by NHS National Services 72 
Scotland (NSS), stakeholders from policy, clinical practice and academia produced a 73 
proposal describing the benefits of, and target deliverables from, the creation of a 74 
national infection informatics resource. Initial funding was secured from Scottish 75 
Government for the initial IIP program from 2013 to 2017.  The programme focused 76 
on three areas:   77 
 Technical platform development to enable linking of varied NHS datasets to 78 
enhance surveillance capability, analysis and responsiveness 79 
 Implementation of proportionate information governance best practices to enable 80 
efficient, agile response to important clinical questions  81 
 Generation of new evidence for improved clinical practice through clinical 82 
exemplar studies using the IIP    83 
Record linkage capability was core to the IIP development.  In NHS Scotland all 84 
individuals have a unique patient identifier - the Community Health Index (CHI) 85 
number – which enables records for the same patient to be linked across multiple 86 
health records data, capturing a patient’s pathway through the healthcare system.7 87 
NHS NSS hosts a range of national health datasets which was the initial focus for 88 
IIP.  On review, these datasets contained a wealth of information applicable to 89 
infection but these were poorly connected and underused by the diverse clinical 90 
communities who could benefit from better integration. Supported by a clinical user 91 
community prioritisation exercise eight datasets were initially selected for inclusion 92 
within the IIP (table1).  93 
Data access is controlled through NSS Information Governance Procedures 94 
ensuring NSS analysts can only access IIP data views for which they have 95 
underlying dataset approval.  In addition, generic ethics and privacy approval for the 96 
conduct of linkage studies under the programme was secured with documentation of 97 
analyses for audit purposes.   98 
Results 99 
The IIP is hosted within the NSS Corporate Data Warehouse (CDW), the central 100 
repository for national datasets, connected by a standardised set of common 101 
dimensions. IIP technical developments enabled the creation of virtual “simplified 102 
views” of each IIP dataset e.g. the SMR01 view joins over 36 tables in a flat-like 103 
structure to expose 50 variables which meet the majority of infection analysis 104 
requirements. Analysts run queries across these views within the IIP statistical 105 
platform. Further functionality includes a cohort solution enabling definition and 106 
extraction of patient cohorts from across datasets, storable for repeated use.8  107 
The main benefits arising from the IIP technical build have been: improved data 108 
security and reduced errors with fewer data extracts (reducing human errors in 109 
multiple file extraction and subsequent linkage) as statistical packages process data 110 
directly in the CDW; better flexibility in running repeated linkages and refreshing 111 
reporting for common queries; and capability to retain and share analysis programing 112 
scripts, backed up within the IIP.   113 
The key deliverable beyond creating the platform and assuring robust governance 114 
was the completion of data linkage studies, pertinent to the clinical community, to 115 
test the agility and robustness of the IIP to inform national policy and antimicrobial 116 
prescribing practice.  This has been delivered through a series of studies under two 117 
broad themes: intended and unintended effects of antimicrobial stewardship and 118 
infection management intervention; and infection risk factors and clinical outcomes, 119 
Table 2 summarises key studies which provide: reassurance to the clinical 120 
community as we seek to safely reduce antimicrobial use; national quantification of 121 
clinical outcomes following a healthcare associated infection (HAI), and; application 122 
of data at scale to identify and quantify risks associated with infection to inform 123 
development of patient centred clinical decision tools.   This evidence is shared with 124 
the clinical community through SAPG, the IIP website, regular newsletters and 125 
publication/presentation at international meetings (Table 2).6 126 
  127 
Platform development and evidence generation has been underpinned by two 128 
components: a skills development programme for analytical and statistical staff 129 
supported through a joint academic-NHS network to build capability and capacity in 130 
infection informatics, and a clinical engagement and communication strategy to build 131 
awareness and knowledge of the IIP potential in supporting infection management 132 
and control.     133 
 134 
Discussion  135 
In Scotland taking a national perspective to infection informatics was logical given: 136 
the population size (approximately 5.3 million); a national, clinically led approach to 137 
antimicrobial stewardship and infection control, and our capability to capture 138 
comprehensive healthcare activity for all citizens. IIP sought to build on earlier 139 
Scottish experiences gained in diabetes through the Scottish Care Information – 140 
Diabetes Collaboration [SCI-DC],9 a national collaboration which has successfully 141 
supported this community in providing and improving patient care, screening 142 
services and data for improvement.10  143 
Previously, Scottish infection publications mainly involved small scale studies11,12 144 
working with local NHS Health Board datasets but the infection community wished to 145 
maximise use of existing data to replicate such studies nationally. This desire, 146 
coupled with the evolving national and international health policy frameworks, 147 
recognising the role of health informatics, provided the environment to articulate the 148 
benefits of investing in a national IIP which has enabled:  149 
 Better identification of the intrinsic and extrinsic risk factors for, and outcomes 150 
from,  infection  151 
 Better clinical decision making through enhanced intelligence on best practice 152 
 More rapid, effective identification of unintended consequences of antimicrobial 153 
misuse 154 
 Improved measurement of health intervention impact on patient outcomes 155 
 Enhanced evidence base to inform policy 156 
Central to our success has been clinical engagement and designated, resourced, 157 
clinical leadership as a component of the program. This leadership has ensured that 158 
IIP aligned with clinical priorities and had a clear translational pathway to impact. 159 
Evidence generation from the exemplar studies is already shaping clinical practice 160 
(table 2).  Moving forward clinicians’ expectations of IIP intelligence are twofold: 161 
incorporation into clinical decision tools available at the point of care to inform 162 
management of individual patient episodes, and timely tailored information 163 
resources, well visualised and clinically meaningful, to drive quality improvement.   164 
Future expansion of the range of datasets available through the IIP must address the 165 
current absence of both national patient level hospital prescribing data and 166 
laboratory data, beyond microbiology.  Both these gaps are recognised in our 167 
eHealth and informatics strategies for Scotland.13,14 A plan for rollout of Hospital 168 
Electronic Prescribing has been secured and the challenge of laboratory datasets is 169 
acknowledged as a priority for action. More collegiate working across NHS, 170 
academia and industry should be part of future solutions to enable more rapid 171 
innovation in data collation and analytics to improve health outcomes. Such an 172 
approach will also enable efficient utilisation of expanding data streams being 173 
generated through technology advancements, including next generation sequencing, 174 
diagnostics and behavioural risk factors.  175 
Encouragingly, we are not alone in the effort to build better intelligence and utilise 176 
routine data and record linkage to improve infectious disease surveillance.2,15,20    177 
Like others we have found generation and use of indicators (AMR, antimicrobial use) 178 
at a population/geographical level, accessible to all stakeholders, is a strong 179 
foundation to identify an agenda for patient level analysis and a move towards point-180 
of-care clinical decision support tools.  Our “build and test phase” has identified a 181 
number of key enablers, potentially transferable to other health care systems: 182 
government/policy support; unique patient identifier; strong clinical engagement and 183 
leadership; collaborative academic research; and technological “know how” with 184 
proportionate information governance.  We are part way along our IIP journey and 185 
have begun to increase our responsiveness to address important clinical questions 186 
that could be answered through a data linkage approach.  We hope our shared 187 
experience will inform and encourage others to embark upon this journey and 188 
catalyse opportunities for global collaboration.   189 
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Table 1: Datasets in NHS Scotland Infection Intelligence Platform  
Note:  NSS monitor data submissions in terms of completeness and quality through the Data Monitoring and Support Service and advise data users of any 
quality/completeness issues impacting on the use of data 
Name Description Update Frequency Earliest data Total number 
of records 
Prescribing Information 
System (PIS) 
Individual patient level data relating to community prescriptions written and 
dispensed within Scotland. 
 
Monthly 2009 ~1.2 billion 
Hospital Medicines 
Utilisation Database (HMUD) 
Non-patient level data sourced from hospital pharmacy stock control 
systems in Scotland containing information on aggregate issues of 
medicines to clinical areas.  
 
Monthly 2009 ~91 million 
Acute Scottish Morbidity 
Record (SMR01) data 
Individual patient level acute inpatient and day case activity data. 
 
Monthly 1997 ~91 million 
Mental health (SMR04) data Individual patient level mental health hospital activity data. 
 
Monthly 1997 ~1 million 
Maternity (SMR02)  data Individual patient level maternity units/hospital discharge data. 
 
Monthly 1981 ~4.5 million 
Deaths (SMR99) data Individual patient level death registrations data from the National Records 
of Scotland 
 
Monthly 1980 ~2.1 million 
Scottish Surgical Site 
Infection Reporting System 
(SSIRS) 
Individual patient level surgical site infection data. Caesarean section and 
hip arthroplasty are the two mandatory procedures required for SSI 
surveillance. 
 
Quarterly 2002 242,000 
Electronic Communication of 
Surveillance in Scotland 
(ECOSS) 
Individual patient level data on key (e.g. bacteraemia) positive 
microbiology laboratory specimen results and a subset of antimicrobial 
susceptibility/resistance data sourced from diagnostic microbiology 
laboratories within NHS Boards and national reference laboratories. 
Monthly 2007 ~29 million 
  
Table 2- Examples of key IIP studies (more information available at http://www.isdscotland.org/Health-Topics/Health-and-Social-
Community-Care/Infection-Intelligence-Platform/Study-Outputs) 
Study  Topic Rationale  Key Results Impact on clinical practice 
Measuring potential 
unintended consequences of 
reducing community 
antimicrobial prescribing16 
Safely reducing antimicrobial use is a 
priority to minimise development of 
AMR but clinicians are concerned that 
initiatives to reduce antimicrobial use 
could result in patients with serious 
infections not receiving treatment. 
The proportion of the Scottish population overall 
exposed to at least one antimicrobial in primary 
care, any time within the year, decreased by 1.6% 
from 32.2% in 2011 to 30.6% in 2014. Whereas 
antimicrobial use in the 30 days prior to admission 
for study patients increased by 1.9% over the 
study period, from 62.8% to 64.7%. 
 
These findings have been disseminated thorough 
national and local networks (SAPG, NHS Boards, IIP 
newsletter) to reassure clinicians that reductions in 
antimicrobial prescribing can be achieved without 
adversely impacting on patients who do require 
antimicrobials for respiratory infections.  
 
This analysis will be repeated on a regular basis to 
continue to reassure clinicians or allow early 
identification of any emerging unintended harm. 
Risk factors for antimicrobial 
resistance in community urine 
isolates17 
 
 
Urinary tract infections (UTI) are 
commonly encountered in primary 
care. Treatment is usually empiric but 
there are concerns about increasing 
resistance to these treatments in 
pathogens causing UTI. 
Analysis of 40984 community urine isolates 2012-
2015 showed older age, increasing co-morbidity, 
care home residence and antimicrobial use were 
associated with resistance and multi-drug 
resistance. Cumulative antimicrobial exposure in 
the six months preceding the isolate had a dose-
response effect. Those prescribed ≥29 defined 
daily doses (DDD) of antimicrobial were 5.53 
(95%CI 4.98-6.14) times more likely to have a 
multi-resistant pathogen. 
These data have been disseminated through national 
and local networks.  The output is now being used to 
design and test a clinical decision support tool which 
will enable clinicians to identify patients, at the point of 
prescribing, who are at higher risk of resistance in 
pathogens causing suspected UTI and thereby optimise 
initial antimicrobial treatment. 
 
 
Changes in HAI outcome over  
time18 
 
 
Surveillance of Clostridium difficile 
infection (CDI) in Scotland monitors 
trends in the number of new cases; 
however, there is no mortality  
information. This study examined 
mortality trends of CDI and 
established risk factors associated 
with death 
There was a decrease in all-cause mortality within 
30 days of diagnosis of CDI between 2009 and 
2013 with a year on year decrease in case-fatality.  
Older patients, those with a greater number of 
illnesses, and certain specific conditions such as 
lung, liver and malignancy were also associated 
with increased mortality. 
Further work focused on identifying those factors 
associated with increased survival will support quality 
improvement initiatives to enhance the clinical care of 
patients with CDI and assure better clinical outcomes. 
 
 
 
Association between 
antimicrobial exposure and 
HAI risk19 
 
 
The contribution of any antimicrobial, 
but particularly broad spectrum 
antimicrobials such as 
cephalosporins, fluoroquinolones, co-
amoxiclav and clindamycin is known 
to be associated with a higher risk of 
CDI but the temporal and cumulative 
association between community use 
of antimicrobials and community 
acquired CDI was not well described. 
Exposure to any antimicrobial but especially high 
risk broad spectrum antimicrobials in the previous 
six months increased the odds of CA-CDI.  
Individuals with ≥29 DDD of high risk antimicrobial 
had an odds ratio of 17.9 (95% CI 7.6-42.2) 
compared to no antimicrobials. 
 
The elevated risk following high risk antimicrobials  
was still present 4-6 months after treatment 
(OR=2.6 (1.7-3.9) 
These findings have been disseminated thorough 
national and local networks, presented internationally 
and now published.  These data are now being used to 
generate risk models to create a decision support tool, 
ready for testing in primary care in 2018.   The outcome 
will be better assessment of the benefit and risk of 
treatment with any specific antimicrobials.  
 
 
 
